Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) FCF Margin (2016 - 2026)

Myriad Genetics has reported FCF Margin over the past 17 years, most recently at 2.81% for Q4 2025.

  • Quarterly FCF Margin rose 139.0% to 2.81% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.67% through Dec 2025, up 163.0% year-over-year, with the annual reading at 1.67% for FY2025, 163.0% up from the prior year.
  • FCF Margin was 2.81% for Q4 2025 at Myriad Genetics, down from 8.9% in the prior quarter.
  • Over five years, FCF Margin peaked at 37.38% in Q1 2021 and troughed at 32.91% in Q4 2023.
  • The 5-year median for FCF Margin is 10.88% (2023), against an average of 9.56%.
  • Year-over-year, FCF Margin tumbled -6940bps in 2022 and then soared 3433bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 3.17% in 2021, then tumbled by -488bps to 12.32% in 2022, then plummeted by -167bps to 32.91% in 2023, then soared by 104bps to 1.42% in 2024, then skyrocketed by 97bps to 2.81% in 2025.
  • Per Business Quant, the three most recent readings for MYGN's FCF Margin are 2.81% (Q4 2025), 8.9% (Q3 2025), and 7.7% (Q2 2025).